178 related articles for article (PubMed ID: 24516021)
1. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
Vaz-Luis I; Keating NL; Lin NU; Lii H; Winer EP; Freedman RA
J Clin Oncol; 2014 Mar; 32(9):927-34. PubMed ID: 24516021
[TBL] [Abstract][Full Text] [Related]
2. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.
Freedman RA; Vaz-Luis I; Barry WT; Lii H; Lin NU; Winer EP; Keating NL
Breast Cancer Res Treat; 2014 Jun; 145(2):491-501. PubMed ID: 24756187
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.
Chavez-MacGregor M; Niu J; Zhang N; Elting LS; Smith BD; Banchs J; Hortobagyi GN; Giordano SH
J Clin Oncol; 2015 Jul; 33(19):2176-83. PubMed ID: 25964256
[TBL] [Abstract][Full Text] [Related]
5. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Azim HA; Agbor-Tarh D; Bradbury I; Dinh P; Baselga J; Di Cosimo S; Greger JG; Smith I; Jackisch C; Kim SB; Aktas B; Huang CS; Vuylsteke P; Hsieh RK; Dreosti L; Eidtmann H; Piccart M; de Azambuja E
J Clin Oncol; 2013 Dec; 31(36):4504-11. PubMed ID: 24248687
[TBL] [Abstract][Full Text] [Related]
6. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
10. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii J; Burstein HJ; Winer EP; Freedman RA
Breast Cancer Res Treat; 2016 Aug; 159(1):151-62. PubMed ID: 27484879
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
12. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
13. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
Reeder-Hayes K; Peacock Hinton S; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2016 Jun; 34(17):2003-9. PubMed ID: 27069085
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Piccart-Gebhart M; Holmes E; Baselga J; de Azambuja E; Dueck AC; Viale G; Zujewski JA; Goldhirsch A; Armour A; Pritchard KI; McCullough AE; Dolci S; McFadden E; Holmes AP; Tonghua L; Eidtmann H; Dinh P; Di Cosimo S; Harbeck N; Tjulandin S; Im YH; Huang CS; Diéras V; Hillman DW; Wolff AC; Jackisch C; Lang I; Untch M; Smith I; Boyle F; Xu B; Gomez H; Suter T; Gelber RD; Perez EA
J Clin Oncol; 2016 Apr; 34(10):1034-42. PubMed ID: 26598744
[TBL] [Abstract][Full Text] [Related]
15. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
16. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
18. Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.
Griffiths RI; Lalla D; Herbert RJ; Doan JF; Brammer MG; Danese MD
Cancer Invest; 2011 Nov; 29(9):573-84. PubMed ID: 21929325
[TBL] [Abstract][Full Text] [Related]
19. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.
Freedman RA; Hughes ME; Ottesen RA; Weeks JC; He Y; Wong YN; Theriault R; Keating NL
Cancer; 2013 Feb; 119(4):839-46. PubMed ID: 23011924
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
De Sanctis R; Giordano L; D'Antonio F; Agostinetto E; Marinello A; Guiducci D; Masci G; Losurdo A; Zuradelli M; Torrisi R; Santoro A
Breast; 2021 Jun; 57():80-85. PubMed ID: 33780903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
